Depomed Announces Third Quarter 2017 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
DepoMed Inc (DEPO) PT Lowered to $6 at RBC Capital Following 3Q Miss
November 8, 2017 8:13 AM ESTRBC Capital lowered its price target on DepoMed Inc (NASDAQ: DEPO) to $6.00 (from $8.00) while maintaining a Sector Perform rating. DEPO reported a 3Q top-line miss and another 2017E guidance step-down. Revenue came in at ~$95 million, below consensus of ~$99 million. Guidance was again lowered by $2030 million to... More
Depomed (DEPO) Tops Q3 EPS by 3c, Revenue Comes in Light
November 7, 2017 4:22 PM ESTDepomed (NASDAQ: DEPO) reported Q3 EPS of $0.14, $0.03 better than the analyst estimate of $0.11. Revenue for the quarter came in at $95 million versus the consensus estimate of $99.57 million.
GUIDANCE:
Depomed sees FY2017 revenue of $375-380 million, versus the consensus of $393.6... More
